Show simple item record

dc.contributor.authorOzieranski, Krzysztof
dc.contributor.authorBalsam, Pawel
dc.contributor.authorKaplon-Cieslicka, Agnieszka
dc.contributor.authorTyminska, Agata
dc.contributor.authorKowalik, Robert
dc.contributor.authorGrabowski, Marcin
dc.contributor.authorPeller, Michal
dc.contributor.authorWancern, Anna
dc.contributor.authorMarchel, Michal
dc.contributor.authorCrespo-Leiro, María Generosa
dc.contributor.authorMaggioni, Aldo P.
dc.contributor.authorDrozdz, Jaroslaw
dc.contributor.authorFilipiak, Krzysztof J.
dc.contributor.authorOpolski, Grzegorz
dc.date.accessioned2019-04-23T07:43:41Z
dc.date.issued2019-01-16
dc.identifier.citationOzieranski K, Balsam P, Kaplon-Cieslicka A, et al. Comparative analysis of long-term outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology. Cardiovasc Drugs Ther. 2019; 33(1): 77-86es_ES
dc.identifier.issn0920-3206
dc.identifier.urihttp://hdl.handle.net/2183/22704
dc.description.abstract[Abstract] Purpose. Current clinical recommendations do not emphasise superiority of any of diuretics, but available reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF). Methods. Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide using propensity score matching. Results. Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; p = 0.03) of worsening ≥ 1 NYHA class. Torasemide use impacted positively upon the primary endpoint occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy. Conclusions. Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.urihttps://doi.org/10.1007/s10557-018-6843-5es_ES
dc.rightsThe final publication is avaliable at Springer Linkes_ES
dc.subjectHeart failurees_ES
dc.subjectLoop diuretices_ES
dc.subjectFurosemidees_ES
dc.subjectTorasemidees_ES
dc.titleComparative analysis of long-term outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiologyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2020-01-16es_ES
dc.date.embargoLift2020-01-16
UDC.journalTitleCardiovascular Drugs and Therapyes_ES
UDC.volume33es_ES
UDC.issue1es_ES
UDC.startPage77es_ES
UDC.endPage86es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record